Objective: While urinary leukotriene E (uLTE) is a validated biomarker for the cysteinyl leukotriene pathway, which is central to the pathophysiology of asthma, atopy, and chronic rhinosinusitis (CRS), the contributions of comorbid asthma and atopy to uLTE levels in various CRS subtypes have not been previously characterized. We sought to (1) identify reference values for uLTE in subjects with and without CRS and (2) determine how the presence of comorbid atopy and asthma affects uLTE levels in CRS.
Setting: Tertiary referral medical center.
Subjects And Methods: A prospective case-control study was conducted to compare uLTE levels between patients with CRS and healthy controls. Urinary LTE levels were measured by enzyme immunoassay and were adjusted for urinary creatinine concentrations (pg/mg Cr). Patients with CRS were stratified by the clinical comorbidities to determine normative uLTE values for patients with CRS with and without comorbid asthma or atopy.
Results: A total of 153 patients (mean age, 47.3; 47.1% female) were included in the study. Patients with CRS demonstrated significantly higher concentrations of uLTE than healthy controls (1652 vs 1065 pg/mg Cr, = .032). Within the group of patients with CRS, comorbid asthma also individually correlated with elevated uLTE levels (1597 pg/mg Cr, = .0098). Patients with CRS who did not have comorbid allergy and asthma, in contrast, did not have statistically higher uLTE levels than healthy controls (1142 pg/mg Cr, = .61).
Conclusion: Urinary LTE serves as a noninvasive measure of the inflammatory state in CRS. Comorbid asthma and atopy contribute to elevated uLTE levels in CRS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0194599819871700 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study.
Int J Cardiol
October 2022
Research and Early Clinical Development, Cardiovascular, Renal and Metabolic, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Background: Leukotrienes are pro-inflammatory vasoactive lipid mediators implicated in the pathophysiology of atherosclerotic cardiovascular disease. We studied the effect of the 5-lipoxygenase-activating protein inhibitor AZD5718 on leukotriene biosynthesis and coronary microvascular function in a single-blind, phase 2a study.
Methods: Patients 7-28 days after myocardial infarction (±ST elevation), with <50% left anterior descending coronary artery stenosis and Thrombolysis in Myocardial Infarction flow grade ≥ 2 after percutaneous coronary intervention, were randomized 2:1:2 to once-daily AZD5718 200 mg or 50 mg, or placebo, in 4- and 12-week cohorts.
Health effects of concurrent ambient and tobacco smoke-derived particle exposures at low concentrations in children with asthma.
J Expo Sci Environ Epidemiol
September 2020
Department of Pediatrics, National Jewish Health, Denver, CO, USA.
Exposure to particulate matter less than 2.5 microns from either ambient pollution (AMB-PM) or secondhand smoke (SHS-PM) have been associated with asthma worsening, but there is little information on effects and relative potency with concurrent exposures. We studied health effects of concurrent exposures to AMB-PM and SHS-PM over a 6-year period in schoolchildren with asthma.
View Article and Find Full Text PDFEstablishing Urinary Leukotriene E as a Diagnostic Biomarker for Chronic Rhinosinusitis with Comorbid Asthma and Atopy.
Otolaryngol Head Neck Surg
November 2019
Department of Otolaryngology, Head and Neck Surgery, Eastern Virginia Medical School, Norfolk, Virginia, USA.
Objective: While urinary leukotriene E (uLTE) is a validated biomarker for the cysteinyl leukotriene pathway, which is central to the pathophysiology of asthma, atopy, and chronic rhinosinusitis (CRS), the contributions of comorbid asthma and atopy to uLTE levels in various CRS subtypes have not been previously characterized. We sought to (1) identify reference values for uLTE in subjects with and without CRS and (2) determine how the presence of comorbid atopy and asthma affects uLTE levels in CRS.
Setting: Tertiary referral medical center.
The utility of biomarkers in diagnosis of aspirin exacerbated respiratory disease.
Respir Res
October 2018
Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland.
Background: Aspirin-exacerbated respiratory disease (AERD) is a distinct eosinophilic phenotype of severe asthma with accompanying chronic rhinosinusitis, nasal polyposis, and hypersensitivity to aspirin. Urinary 3-bromotyrosine (uBrTyr) is a noninvasive marker of eosinophil-catalyzed protein oxidation. The lack of in vitro diagnostic test makes the diagnosis of AERD difficult.
View Article and Find Full Text PDFDiagnostic Accuracy of Urinary LTE4 Measurement to Predict Aspirin-Exacerbated Respiratory Disease in Patients with Asthma.
J Allergy Clin Immunol Pract
November 2019
Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland.
Background: Patients with aspirin-exacerbated respiratory disease (AERD) are distinguished from patients with aspirin-tolerant asthma (ATA) by significantly higher baseline concentrations of urinary leukotriene E (uLTE). However, an overlap between the individual values of the groups exists.
Objective: The objective of this study was to estimate the discriminative value of uLTE concentration in differentiating between patients with AERD and patients with ATA and evaluate the diagnostic accuracy of uLTE measurement alone and added to clinical parameters to predict AERD diagnosis in patients with asthma.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!